CoChat

Plecanatide Is Effective and Safe in the Treatment for Chronic Idiopathic Constipation: Results of a Phase II Trial

Barish, Charles, Dorn, Spencer, Fogel, Ronald P., Patel, Reema, Rosenberg, Jonathan · 2021 · Digestive Diseases and Sciences

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

Background Many patients with chronic idiopathic constipation (CIC) remain unsatisfied with their treatment options. Plecanatide is a pH-sensitive uroguanylin analog that increases fluid and ion movement into the gastrointestinal lumen, softening stools and encouraging motility, while limiting the risk of diarrhea.Aims The objective of this phase 2 study is to evaluate the safety and efficacy of once-daily oral plecanatide in patients with CIC and identify the most effective dose.Methods A 12-week, multicenter, randomized, double-blind, placebo-controlled, dose-ranging study was conducted in patients aged 18-75 years and diagnosed with CIC based on modified Rome III criteria (< 3 complete spontaneous bowel movements [CSBMs] per week and infrequent loose stools without the use of laxatives). Participants were randomized to placebo or plecanatide 0.3, 1.0, or 3.0 mg. The primary efficacy endpoint was the proportion of overall CSBM responders. Key secondary endpoints included time to first CSBM, change in CSBM and spontaneous bowel movement (SBM) frequency rates, patient-reported outcomes, safety, and tolerability.Results Of 951 randomized participants, 946 were included in the modified intent-to-treat population. Plecanatide 0.3 and 3.0 mg significantly increased overall CSBM responder rates compared with placebo (0.3 mg, P = 0.016; 3.0 mg, P = 0.009). Plecanatide was associated with decreased time to first CSBM, significant increases in CSBM and SBM frequency, and decreased patient-reported constipation severity compared with placebo. Diarrhea was the most frequently reported treatment-emergent adverse event.Conclusions Plecanatide is a well-tolerated treatment that relieved the symptoms of CIC with a relatively low incidence of diarrhea.

Overview

Integrity signals

Registry

Crossref · 10.1007/s10620-020-06187-5

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 7 references

Research works printed but not linked: 1

  1. American College of Gastroenterology Chronic Constipation Task Force. An evidence-based approach to the management of chronic constipation in North America. Am J Gastroenterol. 2005;100:S1–S4.

Cited by

See all 8

Metadata

Authors
Barish, C., Dorn, S., Fogel, R. P., Patel, R., & Rosenberg, J.
Affiliations
  • University of North Carolina at Chapel Hill (US)
  • Troy Gastroenterology (US)
  • Bausch Health (United States) (US)
Corresponding author
Patel, Reema
Venue
Digestive Diseases and Sciences
Published
2020-03-17
Volume
66
Issue
2
Pages
537-540
ISSN
  • 0163-2116 (ISSN-L)
  • 1573-2568
OpenAlex
W3012294198
Cited by
8
References
7
Citations by year
2026: 2 · 2025: 1 · 2024: 1 · 2023: 2 · 2022: 2
FWCI
0.87
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Digestive Diseases and Sciences (publishedVersion)
  • PubMed (publishedVersion)
Funders
Salix Pharmaceuticals, Inc.
Topics
  • Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
  • Health Sciences › Medicine › Urology › Pelvic floor disorders treatments
  • Health Sciences › Medicine › Surgery › Congenital gastrointestinal and neural anomalies
Keywords
plecanatide, chronic idiopathic constipation, guanylate cyclase-C agonist, dose-ranging, diarrhea, drug safety and tolerability
MeSH terms
Adolescent, Adult, Aged, Chronic Disease, Constipation, Diarrhea, Dose-Response Relationship, Drug, Double-Blind Method, Female, Gastrointestinal Agents, Humans, Male, Middle Aged, Treatment Outcome, Natriuretic Peptides, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Plecanatide Is Effective and Safe in the Treatment for Chronic Idiopathic Constipation: Results of a Phase II Trial. https://app.cochat.ai/papers/10.1007/s10620-020-06187-5
The paper
Barish, C., Dorn, S., Fogel, R. P., Patel, R., & Rosenberg, J. (2021). Plecanatide Is Effective and Safe in the Treatment for Chronic Idiopathic Constipation: Results of a Phase II Trial. Digestive Diseases and Sciences. https://doi.org/10.1007/s10620-020-06187-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.